
|Videos|December 15, 2017 (Updated: December 19, 2020)
Novel Agent Active in Refractory Polycythemia Vera
Author(s)John O. Mascarenhas, MD
This video highlights results of a phase I study of idasanutlin (RG7388) in patients with refractory polycythemia vera and essential thrombocythemia.
Advertisement
In this video, John O. Mascarenhas, MD, of the Tisch Cancer Institute at Mount Sinai in New York, highlights results of a phase I study of idasanutlin (RG7388) in patients with refractory polycythemia vera and essential thrombocythemia.
Mascarenhas presented results of the study (
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Approval to Teclistamab Combo in RRMM
2
The Evolving Landscape of Immunotherapy in Breast Cancer
3
New Zenocutuzumab Findings Provide Hope for Targeting Rare NSCLC Subtypes
4
Cadonilimab Yields 100% 24-Month OS in Recurrent Cervical Cancer Population
5






















































